Anti-Ras antibody (ab196630)
Key features and details
- Rabbit polyclonal to Ras
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Overview
-
Product name
Anti-Ras antibody
See all Ras primary antibodies -
Description
Rabbit polyclonal to Ras -
Host species
Rabbit -
Specificity
The antibody detects endogenous level of total RAS protein. The immunogen shares 90.5 % of identity with HRAS and NRAS.
-
Tested applications
Suitable for: WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Recombinant fragment corresponding to Human Ras aa 1-100 (N terminal).
Database link: P01116 -
Positive control
- WB: L929 cells, rat muscle, 293 cells IHC: mouse kidney, mouse testis ICC/IF: HeLa cells, NIH/3T3 cells
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
(without Mg2+ and Ca2+) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab196630 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (5) |
1/500 - 1/1000. Predicted molecular weight: 21 kDa.
|
IHC-P |
1/50 - 1/200.
|
|
ICC/IF |
1/50 - 1/200.
|
Notes |
---|
WB
1/500 - 1/1000. Predicted molecular weight: 21 kDa. |
IHC-P
1/50 - 1/200. |
ICC/IF
1/50 - 1/200. |
Target
-
Function
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. -
Involvement in disease
Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC). -
Sequence similarities
Belongs to the small GTPase superfamily. Ras family. -
Post-translational
modificationsPalmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation. -
Cellular localization
Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus. - Information by UniProt
-
Database links
- Entrez Gene: 3265 Human
- Entrez Gene: 3845 Human
- Entrez Gene: 4893 Human
- Entrez Gene: 15461 Mouse
- Entrez Gene: 16653 Mouse
- Entrez Gene: 18176 Mouse
- Entrez Gene: 24525 Rat
- Entrez Gene: 24605 Rat
see all -
Alternative names
- C BAS/HAS antibody
- C HA RAS1 antibody
- C-BAS/HAS antibody
see all
Images
-
All lanes : Anti-Ras antibody (ab196630) at 1/1000 dilution
Lane 1 : Mouse L929 cells
Lane 2 : Rat muscle cells
Predicted band size: 21 kDa
Observed band size: 21 kDa -
Anti-Ras antibody (ab196630) at 1/1000 dilution + Human 293 cells
Predicted band size: 21 kDa
Observed band size: 21 kDa -
Immunofluorescence analysis of mouse NIH/3T3 cells using ab196630.
-
Immunofluorescence analysis of human HeLa cells using ab196630
-
Immunohistochemistry of paraffin-embedded mouse testis using ab196630.
-
Immunohistochemistry of paraffin-embedded mouse kidney using ab196630
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab196630 has been referenced in 1 publication.
- Vinciguerra A et al. Remote postconditioning ameliorates stroke damage by preventing let-7a and miR-143 up-regulation. Theranostics 10:12174-12188 (2020). PubMed: 33204336